Serindere, GozdeOzveren, Neslihan2024-06-122024-06-1220181693-96972355-4800https://doi.org/10.14693/jdi.v25i2.1231https://hdl.handle.net/20.500.14551/20307Severe gingival enlargement (GE) is one of the most commonly observed adverse effects in patients who have undergone renal transplants due to the use of cyclosporine A. Objectives: We aimed to gain more insight into the prevalence of GE in patients with renal transplants. Methods: We searched the PubMed and Web of Science databases for relevant studies from January 1990 to January 2018. Using random effects models, we calculated summary incidence rates and 95% confidence intervals (CIs). Results: A total of 595 patients from 10 studies were included. Patients using cyclosporine A with or without any other drugs had a 62.6% (95% CI, 41.9%-79.5%) incidence of GE. Subgroup analysis according to diagnostic criteria showed that the incidence of GE was lower when using well-defined diagnostic criteria or scoring system. The incidence of GE was 88.2% (95% CI, 80.9%-93.0%) in patients using cyclosporine A with nifedipine. Cyclosporine A without nifedipine was associated with a significantly decreased risk of GE incidence when compared with the combination of cyclosporine A and nifedipine (odds ratio: 0.198; 95% CI, 0.083-0.473; P < 0.001). Conclusions: It is important for all clinicians to know the effects of the aforementioned drugs and the treatment options.en10.14693/jdi.v25i2.1231info:eu-repo/semantics/openAccessCyclosporine AGingival EnlargementGingival OvergrowthRenal TransplantationCyclosporine-AAllograft RecipientsOvergrowthNifedipineHyperplasiaChildrenParametersSeverityArticle252114120N/AWOS:000448648700008